The Epidermal Growth Factor Receptor (EGFR), a cell surface membrane signaling protein, has emerged as one of the most promising molecular targets for anti-cancer therapy. The long-term objective of this research proposal is to gain new information to guide the optimal use of molecular inhibitors of EGFR in cancer patients. The proposed studies will take advantage of newly established EGFR inhibitor-resistant human tumor cells to examine cellular interactions between EGFR inhibitors and radiation, and explore strategies to overcome intrinsic or acquired resistance to EGFR inhibitor therapy. Promising leads from preclinical findings in tumor model systems will then be further examined by molecular analysis of tumor specimens from patients enrolled in a clinical trial. The first scientific aim is to characterize specific differences between EGFR inhibitor-resistant and parental tumor cells with regard to their molecular footprint and radiation response profile. These in vitro and in vivo studies will examine molecular distinctions between EGFR inhibitor-resistant and sensitive tumors, and identify gene and protein expression differences using high-throughput analyses. The second scientific aim is to explore the functional significance of altered protein and gene expression changes with regard to subsequent EGFR inhibitor and radiation response. These preclinical studies will include systematic evaluation of promising molecular targets that may play a role in the resistance mechanism. The third scientific aim is to investigate these molecular targets that characterize the EGFR inhibitor-resistant profile, and correlate their expression with ultimate clinical outcome in human tumor specimens from patients enrolled in a national cancer trial. It is anticipated that these studies will provide valuable information regarding mechanisms of response and resistance to EGFR inhibitors, and thereby facilitate the design of innovative cancer treatment strategies to improve outcome. Public Health Description: Many of our most promising cancer drugs show beneficial impact in only a minority of patients with advanced tumors. The majority of tumors exhibit some form of resistance to drug treatment. In this research proposal, we seek to increase the percentage of cancer patients who benefit from leading cancer drugs through the identification and disabling of specific tumor cell molecules that promote treatment resistance. ? ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA113448-01A1
Application #
7148320
Study Section
Basic Mechanisms of Cancer Therapeutics Study Section (BMCT)
Program Officer
Bernhard, Eric J
Project Start
2006-07-01
Project End
2011-05-31
Budget Start
2006-07-01
Budget End
2007-05-31
Support Year
1
Fiscal Year
2006
Total Cost
$260,925
Indirect Cost
Name
University of Wisconsin Madison
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Huang, Shyhmin; Li, Chunrong; Armstrong, Eric A et al. (2013) Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res 73:824-33
Argiris, A; Kotsakis, A P; Hoang, T et al. (2013) Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 24:220-5
Kimple, Randall J; Harari, Paul M; Torres, Alexandra D et al. (2013) Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts. Clin Cancer Res 19:855-64
Kimple, Randall J; Smith, Molly A; Blitzer, Grace C et al. (2013) Enhanced radiation sensitivity in HPV-positive head and neck cancer. Cancer Res 73:4791-800
Huang, Shyhmin; Benavente, Sergio; Armstrong, Eric A et al. (2011) p53 modulates acquired resistance to EGFR inhibitors and radiation. Cancer Res 71:7071-9
Wheeler, Deric L; Dunn, Emily F; Harari, Paul M (2010) Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 7:493-507
Kruser, Tim J; Wheeler, Deric L; Armstrong, Eric A et al. (2010) Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors. Clin Cancer Res 16:3639-47
Hatakeyama, Hiromitsu; Cheng, Haixia; Wirth, Pamela et al. (2010) Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS One 5:e12702
Benavente, Sergio; Huang, Shyhmin; Armstrong, Eric A et al. (2009) Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clin Cancer Res 15:1585-92
Harari, Paul M; Wheeler, Deric L; Grandis, Jennifer R (2009) Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond. Semin Radiat Oncol 19:63-8

Showing the most recent 10 out of 14 publications